The best treatment for young patients with severe aplastic anemia (SAA) is allogeneic hematopoietic SCT (HSCT), which contributes to long-term survival in about 80-90% of cases. [1] [2] [3] However, the incidence of acute and chronic GVHD in patients who undergo HSCT with a CY-based regimen is still high, occurring in 24-42 and 25-50% of cases. [1] [2] [3] The graft rejection rate is about 5-15% [1] [2] [3] and even higher in patients who receive transfusion 420 U. 4 Fludarabine (Flu) has been found to be effective in T-cell suppression, and is now used worldwide in HSCT for hematologic malignancy and benign hematologic diseases; 5 for SAA the rate of hematopoietic cells engraftment and overall survival was 90-95 and 80-95%, respectively. [6] [7] [8] There are many articles that advocate the use of combined Flu/CY protocols for HSCT in SAA with multiple earlier transfusions. Here we studied the diverse treatment outcomes associated with the use of Flu-based regimens; we reported five patients diagnosed with SAA who underwent HSCT, using the combination of Flu/antithymocyte globulin (ATG) conditioning regimen.
Four of five patients diagnosed with SAA were referred to our center for consideration for HSCT. Four of the five had failed earlier treatment with immunosuppressants. Three patients were more than 40 years of age. In all cases the diagnosis of SAA was confirmed without evidence of paroxysmal nocturnal hemoglobinurea or myelodysplastic syndrome . The time between diagnosis and HSCT ranged between 2 and 23 months. Two patients received transfusions o50 donor units. In patient #5, HSCT was delayed due to donor recruitment problems. One patient (#5) had a tubo-ovarian abscess with febrile neutropenia for 20 days preceding HSCT. All patients had an HLAidentical sibling. The patients' characteristics are shown in Table 1 .
As the conditioning regimen, all patients were treated with Flu/ATG regimen, which consisted of Flu 30 mg/m 2 / day for 6 consecutive days (day -7 to day -2) together with rabbit ATG (Fresenius, Gra¨felfing, Germany) 3.75 mg/kg/day for 4 consecutive days (day -7 to day -4).
For GVHD prophylaxis all patients received cyclosporin 3.0 mg/kg/day i.v. in two divided doses from day À1, to maintain serial levels of 200-250 ng/ml. This was changed to the oral form between days 10 and 14 and was continued at full dose for 5-6 months and then gradually tapered over 6 months. MTX was given i.v. at a dose of 15 mg/m 2 on day 1 and a dose of 10 mg/m 2 on days 3, 6 and 11.
All patients received filgrastim 5 mg/kg/day from day 5 after stem cell infusion until engraftment. Acyclovir was given from day À7 for 3 months. All patients received biweekly trimethoprim-sulfamethoxazole prophylaxis after they recovered from cytopenia.
The day of neutrophil engraftment was defined as the first of three consecutive days with an ANC 40.5 Â 10 9 /l. The day of plts engraftment was defined as the first of three consecutive days with a plt count 420 Â 10 9 /l without plt transfusion. Graft failure was defined as failure to reach an ANC of 0.5 Â 10 9 /l on day 30 from the beginning of stem cell infusion. Graft rejection was defined as a progressive decrease in blood counts after initial engraftment. BM morphology and hematopoietic chimerism were evaluated on days 30, 100, 180 and 360 after stem cell transfusion.
The median age of all patients was 41 years (19-52 years). Median time between diagnosis and HSCT was 7 months (2-23 months). All patients received peripheralblood HSCT. Median total CD34 infusion was 4.18 Â 10 6 / kg (3.3-5.81 Â 10 6 /kg). Median times to neutrophil and plt engraftment were 11 (11-22) and 12 (11-23) days, respectively. Four of the five patients had febrile neutropenia with a median duration of 10 days (5-25 days). Escherichia coli septicemia occurred in patient #5; the source of infection was an infected hematoma after undergoing total abdominal hysterectomy with bilateral salpingo-oophorectomy for treatment of her myoma uteri. Median numbers of packed red cell and plt transfusions during admission were 5 and 6 units, respectively. No evidence of fungal infection, CMV infection and acute GVHD was found. One patient (#4) had oral chronic GVHD of grade II at 7 months after HSCT, but he had responded favorably to treatment with low-dose corticosteroids. Apart from patient #3, who was not evaluated for hematopoietic chimerism, three patients had achieved full donor chimerism at 12 months.
Patient #1 had disease relapse after being exposed to a chemical cleaning agent for 1 month. This relapse was detected on day 300 after HSCT. However, she had complete and sustained engraftment after treatment with a second HSCT using the same donor. The conditioning regimen consisted of Flu/CY/ATG.
At the time of evaluation, with a median follow-up of 15 (6-28) months, all patients were alive and had sustained complete hematopoietic cell engraftment.
In our study, four patients had complete and sustained engraftment with a combination of Flu/ATG conditioning regimen, even though they had many high-risk factors that cause graft rejection: prolonged interval between diagnosis and HSCT, multiple transfusions and failed immunosuppressive therapy. Although all patients received PBSC source, the incidence of chronic GVHD was lower than that reported in earlier studies. 9, 10 No evidence of graft failure or acute GVHD was found in our study. Overall survival rate was 100% and no serious complications occurred after HSCT. Patients more than 40 years of age can tolerate this regimen quite well (Table 2) .
CY-based regimens are used worldwide in HSCT for SAA, but complications such as hemorrhagic cystitis, mucositis, veno-occlusive disease, infertility and myelodysplastic syndrome/secondary leukemia are also noted. Therefore, Flu/ATG conditioning regimen is an acceptable option, which improves the outcomes of HSCT for SAA, causing less toxicity with higher tolerance in patients aged 440 years. The use of an alkylating agent in HSCT from an HLA-identical sibling for SAA might not be necessary. However, as in our study the duration of follow-up was limited and the number of patients was very small, the rate of disease relapse and late complication of the Flu/ATG conditioning regimen should be further explored. Letter to the Editor
